Halaman 4 - Kanker lambung Dokter Terbaik - TOP-145 dokter

Dr. Topcu berspesialisasi dalam kanker lambung dan kanker gastrointestinal lainnya, dengan pelatihan di pusat internasional terkemuka seperti MD Anderson Cancer Center.

• Spesialis onkologi medis dengan pengalaman lebih dari 9 tahun
• Terlatih di MD Anderson Cancer Center dan Sunnybrook Odette Cancer Center
• Bekerja di Valued Med Hub Hospitals
• Berspesialisasi dalam kanker sistem gastrointestinal termasuk kanker lambung

Dr. Kaplan adalah spesialis onkologi radiasi, yang berfokus pada pendekatan perawatan presisi untuk kanker lambung di Medipol Mega University Hospital.

• Menjadi ahli dalam teknik radioterapi tingkat lanjut
• Bekerja dengan tim multidisiplin untuk perawatan komprehensif
• Berdedikasi pada rencana perawatan personal

Prof. Zamir Halperin memimpin Departemen Sistem Pencernaan di Pusat Medis Tel Aviv dengan keahlian puluhan tahun dalam penyakit gastrointestinal dan gangguan hati.

• Direktur Institut Gastroenterologi selama 14 tahun
• Mantan Ketua Asosiasi Gastroenterolog Israel
• Terlatih di Cleveland Clinic Foundation dan Royal Free Hospital
• Profesor di Sekolah Kedokteran Sackler, Universitas Tel Aviv
• Berfokus pada endoskopi tingkat lanjut dan penyakit radang usus

Dr. Joseph Klauzner adalah salah satu ahli bedah terbaik di Israel untuk prosedur Whipple, operasi kunci untuk kanker lambung dan pankreas. Beliau memimpin Departemen Bedah di Sourasky Medical Center.

• Memiliki lebih dari 45 tahun pengalaman bedah
• Spesialisasi dalam bedah gastrointestinal dan pankreas
• Menjadi ahli dalam operasi kolorektal yang kompleks
• Memegang peran senior sebagai Ketua Bedah

Associate Professor Dr. Yusuf Acikgoz memiliki pelatihan onkologi yang luas dari Ohio State University dan berpartisipasi aktif dalam uji klinis internasional.

• Spesialisasi dalam Onkologi Medis dengan fokus pada kanker lambung
• Berpartisipasi dalam studi Fase III CheckMate-649 dan Fortitude-101
• Anggota American Society of Clinical Oncology (ASCO)
• Terlatih di Rumah Sakit Pelatihan dan Penelitian Ankara Numune

Professor Madya Tahsin Ozatli berspesialisasi dalam kanker gastrointestinal di Rumah Sakit Universitas Istinye Liv.

• Pengalaman lebih dari satu dekade di bidang onkologi
• Pernah bekerja di Klinik Onkologi Ankara dan Rumah Sakit Pelatihan Regional Erzurum
• Tersertifikasi dalam penyakit dalam
• Diangkat menjadi Professor Madya pada tahun 2016

Profesor Gül Alco merupakan spesialis onkologi radiasi untuk kanker lambung di Universitas Medipol Istanbul.

• Berpengalaman lebih dari 20 tahun di bidang onkologi radiasi
• Profesor di Universitas Demiroğlu Bilim – melatih dokter spesialis lainnya
• Bekerja di Rumah Sakit Distrik Medipol Acıbadem
• Menyelesaikan residensi di Universitas Kadir Has

Spesialis dalam viroterapi – pendekatan imunologi mutakhir untuk kanker lambung – Dr. Jaunalksne membawa 30+ tahun keahlian ke Pallas Clinic.

• Memimpin Pusat Imunologi Klinis di Rumah Sakit Universitas Klinis Pauls Stradins
• Lulus dari Institut Medis Riga dengan magang di Penyakit Dalam
• Berfokus pada pengobatan imunologi inovatif

Dr. Muzaffer Al berspesialisasi dalam bedah kanker laparoskopi dan onkologi, dengan pelatihan lanjutan dari Universitas Istanbul dan Fakultas Kedokteran KTÜ.

• Berpengalaman lebih dari 20 tahun dalam bedah umum
• Pelatihan lanjutan dalam bedah bariatrik dan antirefluks laparoskopi
• Spesialisasi dalam teknik bedah kanker onkologi laparoskopi
• Lulusan Fakultas Kedokteran Universitas Ondokuz Mayıs

Associate Professor Nail Paksoy berspesialisasi dalam pengobatan kanker lambung di Rumah Sakit Medipol Bahcelievler, dengan pengalaman luas di bidang onkologi medis.

• Tersertifikasi ESMO dalam Onkologi Medis
• Berpartisipasi dalam uji klinis internasional untuk kanker gastrointestinal
• Menerbitkan penelitian tentang kemanjuran rejimen FLOT pada kanker lambung metastatik
• Menyelesaikan pelatihan fellowship di Institut Onkologi Universitas Istanbul

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

Dr. Ozden membawa lebih dari 20 tahun pengalaman dalam kedokteran penyakit dalam dan onkologi medis, dengan pelatihan khusus dari Fakultas Kedokteran Cerrahpaşa yang bergengsi di Universitas Istanbul.

• Menyelesaikan subspesialisasi onkologi medis di Fakultas Kedokteran Universitas Kocaeli
• Memiliki pengalaman luas dalam kedokteran penyakit dalam di berbagai rumah sakit
• Lulus dari Program Kedokteran Bahasa Inggris di Universitas Istanbul

Spesialisasi dalam pengobatan kanker lambung dengan pelatihan ekstensif dalam onkologi medis di Universitas Akdeniz.

• Tersertifikasi dalam onkologi medis dengan pengalaman lebih dari 15 tahun
• Bekerja di Kompleks Rumah Sakit Medical Park Antalya
• Menempuh pendidikan di Universitas Akdeniz, salah satu sekolah kedokteran terkemuka di Turki

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.